Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsTransplantation, HomologousCombined Modality TherapyHodgkin DiseaseTransplantation ConditioningTreatment OutcomeStem CellsCyclophosphamideMultiple MyelomaMelphalanSalvage TherapyGraft vs Host DiseaseLymphoma, Non-HodgkinRemission InductionBone Marrow TransplantationDisease-Free SurvivalAntineoplastic AgentsHematologic NeoplasmsMyeloablative AgonistsRecurrenceEtoposideSurvival RateHematopoietic Stem Cell MobilizationCytarabineHematopoietic Stem CellsSurvival AnalysisLiver TransplantationCarmustineWhole-Body IrradiationGraft SurvivalBusulfanRetrospective StudiesThiotepaVincristineMesenchymal Stem Cell TransplantationBone Marrow PurgingDoxorubicinTransplantation ChimeraPrognosisChemotherapy, AdjuvantFollow-Up StudiesTissue DonorsCord Blood Stem Cell TransplantationTime FactorsLymphoma, Mantle-CellAntigens, CD34AmyloidosisCell TransplantationAntineoplastic Agents, AlkylatingKidney TransplantationDexamethasoneEmbryonic Stem CellsBoronic AcidsAntibodies, Monoclonal, Murine-DerivedPyrazinesGranulocyte Colony-Stimulating FactorLymphoma, FollicularAdult Stem CellsLeukemia, Myeloid, AcuteIfosfamideLymphomaLeukapheresisInduction ChemotherapyHistocompatibility TestingImmunosuppressive AgentsAutograftsLymphoma, T-Cell, PeripheralThalidomidePrednisoneNeoplasm, ResidualMyelodysplastic SyndromesHistocompatibilityPodophyllotoxinLymphoma, Large B-Cell, DiffuseCell DifferentiationLeukemiaGraft vs Leukemia EffectMaintenance ChemotherapyHeart TransplantationCisplatinDose-Response Relationship, DrugPluripotent Stem CellsProspective StudiesMesenchymal Stromal CellsVidarabineTransplantation ImmunologyNeoplasms, Second PrimaryLung TransplantationNeural Stem CellsStem Cell NicheLymphoma, B-CellDrug Administration ScheduleNeoplasm Recurrence, LocalMitoxantroneFatal OutcomeCarboplatin